PRESS RELEASE Washington, D impotance .C. –The American Pharmacists Association Foundationtoday announced the appointment ofChristopher Hocevaras a public person in its Board of Directors for the 2015–2018 term. Hocevar is currently president of Cigna Pharmacy Management, the business’s pharmacy benefits administration business, and also president of Cigna's Select Segment, which targets benefit solutions for groups with 25 to 250 employees. With Cigna since 2002, Hocevar in addition has led the U.S. Individual and Family members Plan Segment and the Emerging Markets Segment. Additionally, he has served as the business enterprise merger and acquisition lead for many of Cigna's acquisitions/partnerships, such as Great-West Healthcare, StarHRG, and health program alliances.
Clear-cell carcinoma and endometrioid carcinoma are the third and second most common types of ovarian cancer; together they account for one quarter of all full cases in North America and a greater proportion in Asia. Our discovery of the dominant mutation in clear-cell ovarian cancers raises expect much needed treatments for this little understood cancers type. Connecting ARID1A gene mutations to endometriotic lesions accelerates us toward the development of equipment to determine which females with endometriosis are at increased risk for ovarian cancers, says Dr. David Huntsman, director of OvCaRe, a partnership system between the BC Malignancy Vancouver and Agency Coastal Health Study Institute and professor, University of British Columbia, Faculty of Medication.